Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Vilma G Duschak

Vilma G Duschak

National Institute of Parasitol, Argentina

Title: Roles of sulfotopes from glycoconjugates (glycoproteins and sulfatides) in trypanosoma cruzy, the causal agent of chagas disease

Biography

Biography: Vilma G Duschak

Abstract

Trypanosoma cruzi, the causative agent of Chagas disease (ChD), contains a major antigen, cruzipain (Cz). Its C-terminal domain (C-T), bears several post-translational modifications The presence of sulfated oligosaccharides was demonstrated in Cz, in a minor antigen with serine-carboxypeptidase activity, and sulfatides Sulfate-bearing glycoproteins in Trypanosomatids are targets of specific immune responses. T. cruzi chronically-infected-subjects mount specific humoral immune responses to sulfated-Cz. In absence of infection, mice immunized with C-T- but not with sulfate-depleted-C-T, showed surprising ultrastructural heart pathological effects. Moreover, the synthetic anionic sugar conjugate NAcGlc6SO3 mimics the N-glycan-linked sulfated epitope (sulfotope) humoral response. Furthermore, the participation of sulfotopes in the immunomodulation by host-parasite interaction via sialic-acid-Ig-like-specific-lectins (Siglec) binding to sulfosialylated glycoproteins as well as in the parasite infection process has been reported. Strickingly, recent evidences involved to sulfotopes and their specific antibodies in the immunopathogenesis and infection processes of the experimental ChD. Interestingly, sera from chronically T. cruzi-infected individuals with mild disease displayed higher levels of IgG2 antibodies specific for sulfated glycoproteins and sulfatides compared with those in more severe forms of the disease, evidencing that T. cruzi sulfotopes are antigenic independently of the sulfated-glycoconjugate type. Ongoing assays indicate that antibodies specific for sulfotopes might play a role as predictors of stability from the early stages of chronic ChD and might be considered biomarkers of human ChD progression.